Targeted drugs plus chemo for HER2-positive rectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests whether a combination of two targeted drugs (trastuzumab and pertuzumab biosimilars) plus chemotherapy can shrink advanced HER2-positive rectal cancer before surgery. It aims to improve response and potentially reduce the need for more aggressive treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- Your rectal cancer is locally advanced (spread nearby but not to distant organs) and HER2-positive.
- Your tumor has no mutations in the RAS or BRAF genes (wild type).
- You have not had any previous cancer treatment for this condition.
- You are in good general health (able to do daily activities with little or no help) and your organs are working well.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs (against HER2) plus a chemotherapy drug called irinotecan for people with HER2-positive colorectal cancer that has spread and has not responded to standard treatments. The goal is to see if this combo can shrink or control the cancer better than current options.
This trial tests a new combination of treatments given before surgery to shrink locally advanced HER2-positive rectal cancer. If you have this type of cancer, this approach might make surgery more successful and possibly allow you to keep your anus.
This Phase 2 study tests whether tucatinib combined with trastuzumab can slow or shrink rectal cancer that is HER2-positive and has certain genetic tumor features. If you qualify, you may benefit from a targeted treatment approach aimed at the HER2 pathway.
This trial tests a combination of short-course radiation, chemotherapy, and two types of immunotherapy (HLX07 and Serplulimab) before surgery for advanced rectal cancer. It aims to see if this approach helps shrink tumors and improve outcomes.
This study tests two new immunotherapy drugs (KN026 and KN046) with or without chemotherapy (XELOX) for people with a specific type of advanced stomach cancer that makes too much HER2 protein. The goal is to see if this combination can shrink tumors or slow the cancer.
This trial tests a combination of two drugs, trastuzumab deruxtecan (SHR-A1811) and pertuzumab, given before surgery to shrink HER2-positive breast cancer. It is for women with stage II or III breast cancer who have not yet had treatment and are in good overall health.
Hear when a new Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.